KEYNOTE-006:帕博利珠单抗或伊匹木单抗治疗晚期黑色素瘤的疗效与PD-L1表达及治疗线次分析
KEYNOTE-006随机III期研究纳入833例晚期黑色素瘤患者,比较帕博利珠单抗与伊匹木单抗。24个月生存率在初治和经治患者中帕博利珠单抗均更高,PD-L1阳性患者中更高,PD-L1阴性患者中相似。结论支持帕博利珠单抗单药作为标准治疗,不受线次或PD-L1状态影响。
要点
- 初治患者24个月PFS帕博利珠单抗31.0% vs 伊匹木单抗14.6%,OS 58.0% vs 44.7%。
- 经治患者24个月PFS帕博利珠单抗25.7% vs 伊匹木单抗11.3%,OS 49.2% vs 37.9%。
- PD-L1阳性患者24个月PFS帕博利珠单抗33.2% vs 伊匹木单抗13.1%,OS 58.4% vs 45.0%。
核心结论
- 帕博利珠单抗单药可作为晚期黑色素瘤标准治疗,无论一线或二线治疗或PD-L1状态。
研究设计与样本
- 随机、开放标签III期KEYNOTE-006研究,834例入组,833例纳入分析,按1:1:1随机分配。
主要发现
- 中位随访33.9个月,帕博利珠单抗在初治和经治患者中24个月PFS和OS均高于伊匹木单抗。
- PD-L1阳性肿瘤患者中帕博利珠单抗24个月PFS和OS高于伊匹木单抗,PD-L1阴性肿瘤患者中两者相似。
- 帕博利珠单抗各亚组安全性与此前报告一致。
关键数值与推荐
- 初治患者24个月PFS:帕博利珠单抗31.0% vs 伊匹木单抗14.6%;OS:58.0% vs 44.7%。
- 经治患者24个月PFS:帕博利珠单抗25.7% vs 伊匹木单抗11.3%;OS:49.2% vs 37.9%。
- PD-L1阳性肿瘤患者24个月PFS:帕博利珠单抗33.2% vs 伊匹木单抗13.1%;OS:58.4% vs 45.0%。
- PD-L1阴性肿瘤患者24个月PFS:帕博利珠单抗14.9% vs 伊匹木单抗无数据;OS:43.6% vs 31.8%。
临床怎么用
- 晚期黑色素瘤选择帕博利珠单抗单药时,无需考虑一线或二线治疗线次或PD-L1表达状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Predictive biomarkers of patients likely to benefit from anti-programmed death 1 inhibitor therapy have clinical relevance. We examined whether line of therapy or tumour programmed death ligand 1 (PD-L1) expression affects the efficacy and safety of pembrolizumab, compared with ipilimumab, in advanced melanoma. METHODS: Of 834 patients enrolled in the randomised, open-label phase III KEYNOTE-006 study, 833 were included in this analysis. Patients were randomly assigned 1:1:1 to receive pembrolizumab 10 mg/kg every 2 or 3 weeks (for 24 months) or ipilimumab 3 mg/kg every 3 weeks (for four doses) until disease progression/intolerable toxicity. This analysis evaluated progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). Data cut-off: 03 November 2016. RESULTS: Of the patients, 60.3% were male, 65.9% were treatment naive and 80.6% had PD-L1-positive tumours (median follow-up was 33.9 months). Twenty-four-month survival rates were higher with pembrolizumab than with ipilimumab in treatment-naive (PFS 31.0% versus 14.6%; OS 58.0% versus 44.7%) and previously treated patients (PFS 25.7% versus 11.3%; OS 49.2% versus 37.9%). Twenty-four-month survival rates were higher with pembrolizumab than with ipilimumab in patients with PD-L1-positive tumours (PFS 33.2% versus 13.1%; OS 58.4% versus 45.0%) and similar in PD-L1-negative tumours (PFS 14.9% versus NR [no data at 24 months for a PFS estimate]; OS 43.6% versus 31.8%). Safety of pembrolizumab by subgroup was consistent with previous reports. CONCLUSIONS: Findings support pembrolizumab monotherapy as standard of care in patients with advanced melanoma, regardless of first- or second-line therapy or PD-L1 status. CLINICALTRIALS. GOV IDENTIFIER: NCT01866319.
引用
- Carlino MS, Long GV, Schadendorf D, et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer. 2018. PMID: 30096704. doi:10.1016/j.ejca.2018.06.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。